[go: up one dir, main page]

PL2613776T3 - Kompozycja oraz sposób naprawy i regeneracji mięśni - Google Patents

Kompozycja oraz sposób naprawy i regeneracji mięśni

Info

Publication number
PL2613776T3
PL2613776T3 PL11822537T PL11822537T PL2613776T3 PL 2613776 T3 PL2613776 T3 PL 2613776T3 PL 11822537 T PL11822537 T PL 11822537T PL 11822537 T PL11822537 T PL 11822537T PL 2613776 T3 PL2613776 T3 PL 2613776T3
Authority
PL
Poland
Prior art keywords
regeneration
composition
muscle repair
muscle
repair
Prior art date
Application number
PL11822537T
Other languages
English (en)
Inventor
Masahiro Iwamoto
Maurizio Pacifici
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45773490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2613776(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of PL2613776T3 publication Critical patent/PL2613776T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL11822537T 2010-09-01 2011-08-31 Kompozycja oraz sposób naprawy i regeneracji mięśni PL2613776T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37899610P 2010-09-01 2010-09-01
PCT/US2011/049905 WO2012030919A2 (en) 2010-09-01 2011-08-31 Composition and method for muscle repair and regeneration
EP11822537.4A EP2613776B1 (en) 2010-09-01 2011-08-31 Composition and method for muscle repair and regeneration

Publications (1)

Publication Number Publication Date
PL2613776T3 true PL2613776T3 (pl) 2021-01-11

Family

ID=45773490

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11822537T PL2613776T3 (pl) 2010-09-01 2011-08-31 Kompozycja oraz sposób naprawy i regeneracji mięśni
PL20171639T PL3721880T3 (pl) 2010-09-01 2011-08-31 Kompozycja i sposób naprawy i regeneracji mięśni

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20171639T PL3721880T3 (pl) 2010-09-01 2011-08-31 Kompozycja i sposób naprawy i regeneracji mięśni

Country Status (20)

Country Link
US (6) US9789074B2 (pl)
EP (3) EP4066826B1 (pl)
JP (1) JP5986570B2 (pl)
CN (2) CN103200937B (pl)
AU (1) AU2011296080B2 (pl)
BR (1) BR112013004685B1 (pl)
CA (1) CA2809374C (pl)
CL (1) CL2013000580A1 (pl)
CO (1) CO6680694A2 (pl)
DK (2) DK3721880T3 (pl)
EA (1) EA026251B1 (pl)
ES (3) ES2975123T3 (pl)
HU (2) HUE051664T2 (pl)
IL (1) IL224973B (pl)
MX (2) MX361414B (pl)
NZ (1) NZ607547A (pl)
PL (2) PL2613776T3 (pl)
PT (1) PT2613776T (pl)
WO (1) WO2012030919A2 (pl)
ZA (1) ZA201301536B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5986570B2 (ja) 2010-09-01 2016-09-06 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 筋修復および再生のための組成物および方法
US11026952B2 (en) 2011-06-16 2021-06-08 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
US11963964B2 (en) 2011-06-16 2024-04-23 President And Fellows Of Harvard College Small molecules for mouse satellite cell proliferation
US9782417B2 (en) 2011-06-16 2017-10-10 Presidents And Fellows Of Harvard College Methods of increasing satellite cell proliferation with kinase inhibitors
ES2834111T3 (es) * 2012-11-08 2021-06-16 Univ Yamaguchi Agente terapéutico para trastornos queratoconjuntivos
US9375439B2 (en) 2013-01-09 2016-06-28 International Stem Cell Corporation Small molecules that promote skin regeneration
WO2014188716A1 (ja) 2013-05-22 2014-11-27 国立大学法人山口大学 網脈絡膜障害の抑制剤
EP3152190B1 (en) 2014-06-04 2024-07-31 Haro Pharmaceutical Inc. 18-20 member bi-polycyclic compounds
US9784665B1 (en) * 2014-12-29 2017-10-10 Flagship Biosciences, Inc. Methods for quantitative assessment of muscle fibers in muscular dystrophy
US11000057B2 (en) * 2015-05-06 2021-05-11 University Of Southern California Fasting mimicking and enhancing diet for treating hypertension and lipid disorders
EP3091084A1 (en) * 2015-05-08 2016-11-09 Université Catholique De Louvain Methods for assessing the purity of a mesenchymal stem cells preparation
EP3411040A4 (en) * 2016-02-01 2020-07-29 President and Fellows of Harvard College SMALL MOLECULES FOR THE PROLIFERATION OF MOUSE SATELLITE CELLS
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
CA3043807A1 (en) 2016-11-16 2018-05-24 Clementia Pharmaceuticals Inc. Methods for treating multiple osteochondroma (mo)
CA3019069A1 (en) * 2018-04-02 2019-10-02 Hubit Genomix, Inc. Prophylactic and/or therapeutic drug for diabetic nephropathy
US11135236B2 (en) * 2018-04-10 2021-10-05 Northwestern University Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
FR3112684B1 (fr) * 2020-07-24 2022-08-12 Univ Grenoble Alpes Composés pour le traitement de l’hémophilie
CN117244064A (zh) * 2022-06-16 2023-12-19 中国科学院动物研究所 促进哺乳动物器官再生修复的物质及其应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0139676B1 (en) 1983-02-04 1992-11-25 Cytoclonal Pharmaceutics Inc. Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
JPS6253981A (ja) 1985-09-02 1987-03-09 Koichi Shiyudo 新規安息香酸誘導体
AU618590B2 (en) 1988-04-11 1992-01-02 Allergan, Inc. Tetralin esters of phenols or benzoic acids having retinoid like activity
CA2129773C (en) 1993-09-02 2007-05-01 Michael Klaus Aromatic carboxylic acid derivatives
US5408002A (en) 1993-09-09 1995-04-18 Minnesota Mining And Manufacturing Company Azlactone-functional polymer blends, articles produced therefrom and methods for preparing both
US5498795A (en) 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5807900A (en) 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5624957A (en) 1995-06-06 1997-04-29 Bristol-Myers Squibb Company Rary-specific retinobenzoic acid derivatives
FR2739557B1 (fr) 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5726191A (en) 1995-11-16 1998-03-10 Hoffmann-La Roche Inc. Aromatic carboxylic acid esters
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
FR2747041B1 (fr) 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
EP0989855A4 (en) * 1997-05-13 2002-06-12 Osiris Therapeutics Inc REGENERATION OF CARTILAGE IN OSTEOARTHRITIS BY MEANS OF HUMAN MESENCHYMAL STEM CELLS
US7514074B2 (en) * 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US6387367B1 (en) 1998-05-29 2002-05-14 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU6056599A (en) 1998-09-24 2000-04-10 Bristol-Myers Squibb Company Active enantiomer of rargamma-specific agonist
JO2178B1 (en) 1999-10-19 2003-04-23 اف . هوفمان لاروش ايه جي Treatment of invasive diseases, using selected anti-PAR materials
US20030114482A1 (en) 1999-12-15 2003-06-19 Maurizio Pacifici Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies
US6313168B1 (en) 1999-12-15 2001-11-06 Allergan Sales, Inc. Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
EP1265637A2 (en) 2000-03-14 2002-12-18 The University Of Western Ontario Compositions and methods for affecting osteogenesis
DE60120151D1 (de) 2000-04-28 2006-07-06 Childrens Medical Center Isolierung von mesenchymalen stammzellen und deren verwendung
ATE413375T1 (de) 2000-10-02 2008-11-15 Hoffmann La Roche Retinoide zur behandlung von emphysem
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
KR100896550B1 (ko) 2001-09-18 2009-05-07 에프. 호프만-라 로슈 아게 알킬 우레아 레티노이드 작용제 ｉ
BR0212607A (pt) 2001-09-18 2004-08-17 Hoffmann La Roche Agonistas retinóides ii de uréia substituìda
AUPR892501A0 (en) * 2001-11-16 2001-12-13 Peter Maccallum Cancer Institute, The Method of enhancing self renewal of stem cells and uses thereof
US7592174B2 (en) 2002-05-31 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Isolation of mesenchymal stem cells
EP1513803B1 (en) * 2002-06-04 2008-06-18 Galderma Research & Development Ligands that are inhibitors of the rar receptors
US20060035851A1 (en) * 2002-07-03 2006-02-16 Bianchi Marco E Use of hmgb1 in the treatment of tissue damage and or to promote tissue repair
JP2005532810A (ja) 2002-07-16 2005-11-04 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 組織修復および組織形成のために間葉性幹細胞を移植する方法
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
EP1711207B1 (en) 2003-12-10 2012-11-28 Medarex, Inc. Interferon alpha antibodies and their uses
JP2005206544A (ja) * 2004-01-23 2005-08-04 Yasuyoshi Uchida 筋肉再生剤
AU2005240078A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005115304A2 (en) 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating fibrodysplasia
US7345931B2 (en) 2005-08-01 2008-03-18 Infineon Technologies Ag Maintaining internal voltages of an integrated circuit in response to a clocked standby mode
FR2894959B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteur rar-gamma
FR2894960B1 (fr) 2005-12-15 2008-02-29 Galderma Res & Dev Derives biphenyliques agonistes selectifs du recepteurs rar-gamma
KR20080089512A (ko) 2006-01-26 2008-10-06 콤비네이토릭스, 인코포레이티드 근골격계 질환 및 이와 관련된 증상을 치료하기 위한 방법,조성물 및 키트
JP5113038B2 (ja) * 2006-03-23 2013-01-09 テムリック株式会社 癌治療用キットおよび癌治療用医薬組成物
CA2647275A1 (en) 2006-03-31 2007-10-11 F. Hoffmann-La Roche Ag Process for preparing retinoid compounds
JP2009537540A (ja) 2006-05-16 2009-10-29 ビテ ファーマシューティカルズ， インコーポレイテッド 化学療法および／または放射線療法の副作用を処置するためのｒａｒアンタゴニストまたはｒａｒインバースアゴニストの使用
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
EP2265603B1 (en) 2008-03-13 2014-05-07 The General Hospital Corporation Inhibitors of the bmp signaling pathway
WO2010071583A1 (en) 2008-12-18 2010-06-24 Astrazeneca Ab Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient
EP2393915A4 (en) * 2009-02-05 2012-12-26 Regenertech Pty Ltd PROCESS FOR THE PREPARATION OF PRECURSOR CELLS FROM DIFFERENTIATED CELLS
US20120277156A1 (en) 2009-07-21 2012-11-01 University Of Washington Trhough It's Center For Commercialization Inhibition of pathological bone formation
UA50725U (ru) * 2009-12-01 2010-06-25 Институт Нейрохирургии Им. Акад. А.П. Ромоданова Амн Украины Способ лечения больных с прогрессирующей мышечной дистрофией трансплантацией миобластов эмбриона человека
JP5986570B2 (ja) 2010-09-01 2016-09-06 トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ 筋修復および再生のための組成物および方法
CN103702967A (zh) 2011-03-14 2014-04-02 貝丝以色列女执事医疗中心 用于治疗增殖性病症的方法和组合物
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013006372A1 (en) 2011-07-01 2013-01-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of treating pathologic heterotopic ossification
KR102083041B1 (ko) 2012-02-22 2020-05-27 샌포드 번햄 프레비즈 메디컬 디스커버리 인스티튜트 술폰아미드 화합물 및 ｔｎａｐ 억제제로서 용도
JP6430383B2 (ja) 2012-09-28 2018-11-28 ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ 選択的ｂｍｐ阻害剤としての縮合複素環化合物
EP2964651A4 (en) 2013-03-04 2016-11-30 Brigham & Womens Hospital BMP HEMMER AND METHOD OF USE THEREOF
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
WO2014188716A1 (ja) 2013-05-22 2014-11-27 国立大学法人山口大学 網脈絡膜障害の抑制剤
JP2017536411A (ja) 2014-10-01 2017-12-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害用組成物及びｂｍｐ阻害方法
WO2017070194A1 (en) 2015-10-19 2017-04-27 The Children's Medical Center Corporation Method to inhibit endothelial-to-mesenchymal transition
EP3393474B1 (en) 2015-12-24 2023-07-19 The Regents of The University of Michigan Method of treating heterotopic ossification
ES2963348T3 (es) 2016-06-08 2024-03-26 Clementia Pharmaceuticals Inc Métodos para tratar la osificación heterotópica
JP6630255B2 (ja) 2016-09-30 2020-01-15 株式会社沖データ 画像形成装置及び通信システム

Also Published As

Publication number Publication date
MX361414B (es) 2018-12-05
US9314439B2 (en) 2016-04-19
US20140363402A1 (en) 2014-12-11
US12023312B2 (en) 2024-07-02
EP2613776A4 (en) 2014-03-12
US20230201146A1 (en) 2023-06-29
JP2013536855A (ja) 2013-09-26
ZA201301536B (en) 2015-06-24
US11433039B2 (en) 2022-09-06
EP3721880A1 (en) 2020-10-14
IL224973B (en) 2018-06-28
AU2011296080B2 (en) 2014-12-04
DK2613776T3 (da) 2020-10-19
CA2809374C (en) 2021-02-23
PL3721880T3 (pl) 2022-05-23
CA2809374A1 (en) 2012-03-08
NZ607547A (en) 2015-06-26
EP3721880B1 (en) 2022-02-02
CL2013000580A1 (es) 2013-07-12
CO6680694A2 (es) 2013-05-31
WO2012030919A3 (en) 2012-07-05
HUE059024T2 (hu) 2022-10-28
ES2823234T3 (es) 2021-05-06
BR112013004685A2 (pt) 2019-04-24
US10292954B2 (en) 2019-05-21
EP2613776B1 (en) 2020-07-29
US20250108022A1 (en) 2025-04-03
EA026251B1 (ru) 2017-03-31
US20140303223A1 (en) 2014-10-09
CN103200937A (zh) 2013-07-10
ES2912593T3 (es) 2022-05-26
US20180000762A1 (en) 2018-01-04
CN111773213A (zh) 2020-10-16
WO2012030919A2 (en) 2012-03-08
US20200069620A1 (en) 2020-03-05
EA201370051A1 (ru) 2014-03-31
ES2975123T3 (es) 2024-07-03
PT2613776T (pt) 2020-10-21
HUE051664T2 (hu) 2021-03-29
MX2018015032A (es) 2021-12-08
CN103200937B (zh) 2020-07-03
EP4066826A1 (en) 2022-10-05
EP2613776A2 (en) 2013-07-17
EP4066826B1 (en) 2024-03-06
MX2013002275A (es) 2013-05-22
AU2011296080A1 (en) 2013-03-14
DK3721880T3 (da) 2022-05-09
EP4066826C0 (en) 2024-03-06
JP5986570B2 (ja) 2016-09-06
BR112013004685B1 (pt) 2021-09-21
US9789074B2 (en) 2017-10-17
CN111773213B (zh) 2023-02-24

Similar Documents

Publication Publication Date Title
HUE051664T2 (hu) Összetétel és módszer az izomjavításra és a regenerációra
SG2014010706A (en) Method and composition
ZA201403803B (en) Composition,apparatus,kit and method and uses thereof
GB201016001D0 (en) Composition and method
ZA201208578B (en) Composition,method and use
PL2789684T3 (pl) Sposoby i kompozycje do ułatwiania regeneracji
GB201122195D0 (en) Composition and method
GB201408236D0 (en) Composition and method
GB201213490D0 (en) Method and composition for enhanced hydrocarbons recovery
EP2575825A4 (en) COMPOSITIONS AND METHODS FOR TREATING DEPRESSION
ZA201303949B (en) Compounds and methods for skin repair
GB0912468D0 (en) Composition and method
SG11201400909WA (en) Composition and method for producing same
GB201003531D0 (en) Composition and method
IL231489A0 (en) Preparation and method for treating an autoimmune disease
EP2597351A4 (en) LIGHTING INSTALLATION AND METHOD OF USE
PL392720A1 (pl) Kompozycja piwa oraz sposób wytwarzania piwa
EP2616085A4 (en) COMPOSITIONS AND METHOD FOR PROMOTING MUSCULO-SKELETAL REPAIR
GB201106433D0 (en) Composition and method
GB201008843D0 (en) Method and composition
GB201008364D0 (en) Composition and method
PL2606032T3 (pl) Kompozycja i sposoby terapii glejakaep
GB201012680D0 (en) Pothole repair method and apparatus
GB0901667D0 (en) Composition and method
EP2580066A4 (en) PRINTING METHOD AND PRE-TREATMENT COMPOSITION